The Vanguard Group, Inc. ( IRSH) Form 8.3 - The Vanguard Group, Inc.: Strongbridge Biopharma plc 03-Jun-2021 / 14:05 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =---------------------------------------------------------------------------------------------------------------------- Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1) The Vanguard Group, Inc. Company dealt in Strongbridge Biopharma plc Class of relevant security to which the dealings being disclosed relate (Note 2) USD0.01 Ordinary Shares Date of dealing 01 June 2021
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Long Short Numbers (%) Numbers (%) (1) Relevant securities 2,316,064 3.42% (2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total 2,316,064 3.42%
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: Long Short Numbers (%) Numbers (%) (1) Relevant securities (2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total
Ap20
1. Dealings (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5) Sale 35 2.49 USD Purchase 16 2.49 USD
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit e.g. CFD (Note 6) (Note 7) (Note 5) Not Applicable
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of securities to Type, e.g. Option money paid/ purchasing, varying which the option relates Exercise American, Expiry received per unit e.g. call etc. (Note 7) price European etc. date (Note 5) option Not Applicable
(ii) Exercising
Product name, Exercise price per unit (Note 5) Number of securities e.g. call option Not Applicable
(e) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction Price per unit Details (Note 8) (if applicable) (Note 5) Not Applicable
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 03 June 2021
Contact name Shawn Acker
Telephone number 001-610-669-8989
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10) -----------------------------------------------------------------------------------------------------------------------
Category Code: RET - Strongbridge Biopharma plc
TIDM: IRSH
LEI Code: 5493002789CX3L0CJP65
Sequence No.: 109195
EQS News ID: 1204145
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1204145&application_name=news
(END) Dow Jones Newswires
June 03, 2021 09:06 ET (13:06 GMT)